Member Publications

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study

Immune Checkpoint Inhibitor associated Remitting Seronegative Symmetrical Synovitis with Pitting Edema (ICI-RS3PE): Description of a New Entity by CanRIO

De novo Connective Tissue Disorders as Immune-related Adverse Events

Adverse Events Associated with Immune Checkpoint Blockade

Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Immune Checkpoint Inhibitors in Cancer Immunotherapy

Moving towards personalized treatments of immune-related adverse events

Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy

Khashayar Esfahani, Marie Hudson, Gerald Batist

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients

Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis

Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist

Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments

Checking in with immune checkpoint inhibitors: Results of a needs assessment survey of Canadian rheumatologists

Adverse events associated with immune checkpoint inhibitor treatment for cancer

Rheumatic Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors for Cancer: Coming soon to a clinic near you.